Thromb Haemost 1977; 37(02): 216-221
DOI: 10.1055/s-0038-1649222
Original Article
Schattauer GmbH

In Vitro and in Vivo Measurement of Total Antiplasmin Activity

Osamu Matsuo
1   Department of Physiology, Miyazaki Medical College 5200 Kihara, Kiyotake-cho, Miyazaki-gun, Miyazaki-ken, 889–16, Japan
,
Hisashi Mihara
1   Department of Physiology, Miyazaki Medical College 5200 Kihara, Kiyotake-cho, Miyazaki-gun, Miyazaki-ken, 889–16, Japan
› Author Affiliations
Further Information

Publication History

Received 14 July 1976

Accepted 28 November 1976

Publication Date:
03 July 2018 (online)

Summary

Total antiplasmin was measured in vitro and in vivo. In the former case, rabbit plasma was mixed with various concentrations of Urokinase (UK) and the least concentration for appearance of fibrinolytic activity was estimated. This concentration was multiplied by the plasma volume of the rabbit to give the in vitro total antiplasmin. The mean value for 14 rabbits was 4,068.6 units.

In order to estimate the total antiplasmin in vivo, UK solution was infused into rabbits. The infusion speed was multiplied by the time of the first appearance of fibrinolytic activity to give the total antiplasmin, although when the infusion speed was low, fibrinolytic activity did not appear during infusion. The mean in vivo total antiplasmin calculated for 6 cases where the infusion speed was high and fibrinolytic activity was observed, was 28,699.8 units, i.e. about 7 (range, 3-11) times the in vitro value.

 
  • References

  • 1 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Archives of Biochemistry and Biophysics 1952; 40: 346
  • 2 Bernik M.B, Kwaan H.C. Inhibitors of fibrinolysis in human tissues in culture. American Journal of Physiology 1971; 221: 916
  • 3 Blatrix C, Israel J, Audran R, Drouet J, Amouch P, Steinbuch M. Plasma clearance of human antiproteinase/proteinase complexes. In: Fritz H, Tschesche H, Greene L, Truscheit E. (ed.) Bayer-Symposium V. Proteinase inhibitors Springer-Verlag: Berlin; 1974: p. 106
  • 4 Fischer M. Influence of thrombolytic therapy on human antiplasmin. In Mammen E.F, Anderson G.F, Barnhardt M.I. Thrombolytic therapy, Thrombosis et Diathesis haemor-rhagica. Sup 1971; 47: p. 153
  • 5 Gans H, Edson J.R, Tan B.H, Ebert R.V. Recurrent thromboembolism: Report of a case and inquiry into the nature of the fast antiplasmin. Surgery 1969; 66: 1014
  • 6 Hawkey C.M, Stafford J.L. A standard clot method for the assay of plasminogen activators, antiactivators, and plasmin. Journal of Clinical Pathology 1964; 17: 175
  • 7 Matsuo O, Mihara H, Rokushima Y. Assessment the thrombolytic effect of low urokinase concentrations. Acta Haematologica Japonica 1976; a 39: 298
  • 8 Matsuo O, Mihara H, Rokushima Y. Relation between UK concentration in plasma and administrated dosage of UK. Abstract of the Fourth Congress of Japanese Society on Thrombosis and Hemostasis (in press) 1976 b
  • 9 Naeye R.L. Thrombotic disorders with increased levels of antiplasmin and antiplasminogen. New England Journal of Medicine 1961; 265: 867
  • 10 Nilsson I.M, Krook H, Sternberg N.-H, Söderberg E, Söderstorm N. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Medica Scandinavica 1961; 769: 323
  • 11 Schmer G, Branson H.E. A solid-phase radioassay for the quantitative determination of antiplasmin activity in human plasma. British Journal of Haematology 1975; 117
  • 12 Shamash Y, Rimon A. The plasmin inhibitors of plasma. I. A method for their estimation. Thrombosis et Diathesis haemorrhagica 1964; 12: 119
  • 13 Spöttl F, Holzknecht F. The influence of inhibitors of plasmin and plasminogen activation on the streptokinase-induced fibrinolytic state. Thrombosis et Diathesis haemorrhagica 24 1970; 100